Reversal of abnormal coronary vasomotion by calcium antagonists in patients with hypercholesterolemia

Circulation

Volumn 97, Issue 14, 1998, Pages 1348-1354

  Kaufmann, Philipp A ^a   Frielingsdorf, Jürgen ^a   Mandinov, Lazar ^b   Seiler, Christian ^b   Hug, Rosy ^a   Hess, Otto M ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiography; Calcium channels; Cholesterol; Endothelium; Vasodilation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIHYDROPYRIDINE DERIVATIVE; GLYCERYL TRINITRATE; NICARDIPINE; NIFEDIPINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL TONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0032515906     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.14.1348     Document Type: Article

References (45)

1. Brown BG, Bolson EL, Dodge HT. Dynamic mechanisms in human coronary stenosis. Circulation. 1984;70:917-922.
2. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation. 1986;73:865-876.
3. Gordon JB, Ganz P, Nabel EG, Fish RD, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest. 1989;83:1946-1952.
4. Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 1984;24:175-197.
5. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature. 1983;305:627-630.
6. Brown BG, Lee AB, Bolson EL, Dodge HT. Reflex constriction of significant coronary stenosis as a mechanism contributing to ischemic left ventricular dysfunction during isometric exercise. Circulation. 1984;70:18-24.
7. Matsuda Y, Ogawa H, Moritani K, Fujii T, Yoshino F, Katayama K, Miura T, Toma Y, Matsuda M, Kusukawa R. Coronary angiography during exercise-induced angina with ECG changes. Am Heart J. 1984;108:959-966.
8. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989;80:458-465.
9. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation. 1988;77:43-52.
10. Newman CM, Maseri A, Hackett DR, el Tamimi H, Davies GJ. Response of angiographically normal and atherosclerotic left anterior descending coronary arteries to acetylcholine. Am J Cardiol. 1990;66:1070-1076.
11. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
12. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
13. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994;93:50-55.
14. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 1993;88:2139-2148.
15. Frielingsdorf J, Kaufmann P, Seiler C, Vassalli G, Suter T, Hess OM. Abnormal coronary vasomotion in hypertension: role of coronary artery disease. J Am Coll Cardiol. 1996;28:935-941.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
17. Nicardipine Hydrochloride: Information for Clinical Investigators. Palo Alto, Calif: Institute of Clinical Medicine, Syntex Research, Stanford Industrial Park; 1991;VII:1-7.
18. Kaufmann P, Vassalli G, Utzinger U, Hess OM. Coronary vasomotion during dynamic exercise: influence of intravenous and intracoronary nicardipine. J Am Coll Cordiol. 1995;26:624-631.
19. Yabana H, Nagao T, Sato M. Cardiovascular effects of the metabolites of diltiazem in dogs. J Cardiovasc Pharmacol. 1985;7:152-157.
20. Brown BG, Bolson E, Petersen RB, Pierce CD, Dodge HT. The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response. Circulation. 1981;64:1089-1097.
21. Buechi M, Hess OM, Kirkeeide RL, Suter T, Muser M, Osenberg HP, Niederer P, Anliker M, Gould KL, Krayenbuehl HP. Validation of a new automatic system for biplane quantitative coronary arteriography. Int J Card Imaging. 1990;5:93-103.
22. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
23. Tanner FC, Noll G, Boulanger CM, Luscher TF. Oxidized low-density lipoproteins inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 1991;83:2012-2020.
24. Matsuzaki M, Gallagher KP, Patritti J, Tajimi T, Kemper WS, White FC, Ross J Jr. Effects of a calcium-entry blocker (diltiazem) on regional myocardial flow and function during exercise in conscious dogs. Circulation. 1984;69:801-814.
25. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
26. Wems SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation. 1989;79:287-291.
27. Shimokawa H, Vanhoutte PM. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res. 1989;64:900-914.
28. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
29. Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature. 1987;327:237-239.
30. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidized low-density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-1197.
31. Drexler H, Fischell TA, Pinto FJ, Chenzbraun A, Botas J, Cooke JP, Alderman EL. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. Circulation. 1994;89:1615-1623.
32. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
33. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 1995;26:1615-1622.
34. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
35. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530-1538.
36. Habib JB, Bossaller C, Wells S, Williams C, Morrisett JD, Henry PD. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res. 1986;58:305-309.
37. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 1981;68:1366-1369.
38. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet. 1990;335:1109-1113.
39. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82:1940-1953.
40. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986;315:423-429.
41. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol. 1990;66:779-785.
42. The Israeli Sprint Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9: 354-364.
43. Behar S, Zion M, Reicher RH, Kaplinsky E, Goldbourt U, for the SPRINT Study Group. Short- and long-term prognosis of patients with a first acute myocardial infarction with concomitant peripheral vascular disease. Am J Med. 1994;96:15-19.
44. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
45. Felder L, Vassalli G, Vassalli F, Jiang Z, Grimm J, Krayenbuehl HP, Hess OM. Clinical significance of coronary flow reserve: effect of papaverine and exercise. Coron Artery Dis. 1994;5:347-358.